|Mr. Andrew David William Newland||Founder, CEO & Exec. Director||244k||N/A||1962|
|Mr. Ian Francis Griffiths||CFO, Fin. Director, Company Sec. & Exec. Director||153k||N/A||1965|
|Dr. Madeline Repollet||Head of Clinical Laboratories||N/A||N/A||N/A|
|Ms. Anne-Sophie Pailhes-Jimenez||Head of R&D - ANGLE Europe Ltd.||N/A||N/A||N/A|
|Mr. Paul Smith||VP & Chief Exec. Officer of ANGLE Biosciences Inc||N/A||N/A||N/A|
|Mr. Martin Cooke||Director of Manufacturing & Regulatory Affairs||N/A||N/A||1969|
|Mr. Michael O'Brien||Bus. Devel. Director||N/A||N/A||N/A|
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.